Investments
266Portfolio Exits
13Funds
6About Legend Star
Legend Star, a venture capital subsidiary of Legend Holdings, focuses on early-stage angel investments and in-depth incubation. It mainly invests in areas such as artificial intelligence, TMT, and healthcare.

Want to inform investors similar to Legend Star about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Legend Star News
Dec 22, 2022
Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of a $100 million Series D financing round. Co-led by SDIC Fund Management and Tigermed, this round of financing is participated by Legend Star, Wuxi Biologicals Healthcare Ventures, Triwise Capital, Qingdao Mukui, Guolian Industrial Investment, Tian Ge Interactive, etc. Proceeds from the financing will be used to accelerate the development of ongoing clinical and preclinical programs, expand drug portfolio through in-house R&D capability, in-licensing, mergers, and acquisitions, and other strategic collaborations. "We intend to develop differentiated and innovative oncology drugs globally to address the unmet medical needs and aspire to transform deadly cancer into a chronic and eventually a curable disease," said Carsten Lu, President, and CEO of Adlai Nortye. "This round of financing represents an important milestone for Adlai Nortye, and we are honored to continue gaining support from our prestigious new and existing investors as Adlai Nortye has demonstrated a proven track record of delivering what we promised to the market and investors in the previous rounds. We are well-positioned to advance the development of our robust therapeutics pipeline and looking forward to bringing in more and more innovative treatments benefiting patients globally." "We have strong conviction in innovation and paying close attention to what is trending in the biopharmaceutical industry," said Dazhong Lv, Managing Director of SDIC Fund Management. "Adlai Nortye's strategic vision in global market, dedication to innovation in research, and strong execution capability are what have been attracting us. We are pleased to have the opportunity to lead Adlai Nortye's D round and look forward to the development of multiple first-in-class drugs from the company's innovative pipeline globally and in China." Yan Leng, partner of Legend Star added, "Adlai Nortye is quickly emerging as a leader in the field of oncology and we are delighted to have invested in Adlai Nortye and provided support for the R&D of the company's promising pipeline. Combining innovative research and advanced clinical assets with proven management experience, Adlai Nortye has built an exciting portfolio filled with opportunities. We are excited to join such an experienced and proven management team, an outstanding group of investors, and top-tier pharmaceutical partners to advance the company's pipeline products." Share this article:
Legend Star Investments
266 Investments
Legend Star has made 266 investments. Their latest investment was in Leishen Intelligent as part of their Series B on January 1, 2023.

Legend Star Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/3/2023 | Series B | Leishen Intelligent | Yes | 1 | ||
11/29/2022 | Series A | Rgenta Therapeutics | $52M | No | AstraZeneca CICC Healthcare, Boehringer Ingelheim Venture Fund, Delos Capital, Kaitai Capital, Korea Investment Partners, Legend Star, Matrix Partners China, Undisclosed Investors, and Vivo Capital | 12 |
9/19/2022 | Seed VC | CarbonSiliconAI | $7M | Yes | 1 | |
6/16/2022 | Seed VC | |||||
5/26/2022 | Seed VC - III |
Date | 1/3/2023 | 11/29/2022 | 9/19/2022 | 6/16/2022 | 5/26/2022 |
---|---|---|---|---|---|
Round | Series B | Series A | Seed VC | Seed VC | Seed VC - III |
Company | Leishen Intelligent | Rgenta Therapeutics | CarbonSiliconAI | ||
Amount | $52M | $7M | |||
New? | Yes | No | Yes | ||
Co-Investors | AstraZeneca CICC Healthcare, Boehringer Ingelheim Venture Fund, Delos Capital, Kaitai Capital, Korea Investment Partners, Legend Star, Matrix Partners China, Undisclosed Investors, and Vivo Capital | ||||
Sources | 1 | 12 | 1 |
Legend Star Portfolio Exits
13 Portfolio Exits
Legend Star has 13 portfolio exits. Their latest portfolio exit was Singsound on November 08, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
11/8/2021 | Acquired | 1 | |||
10/27/2021 | Acquired | 8 | |||
7/8/2021 | IPO | Public | 2 | ||
Date | 11/8/2021 | 10/27/2021 | 7/8/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 | 8 | 2 |
Legend Star Fund History
6 Fund Histories
Legend Star has 6 funds, including 四期人民币基金 (RMB Fund IV).
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
9/30/2020 | 四期人民币基金 (RMB Fund IV) | $119.18M | 1 | ||
2/2/2018 | Legend Star Fund III | ||||
1/15/2013 | Suzhou Xinglian Tongdao Angel Investment Center LP | ||||
12/1/2009 | Legend Star Angel Fund | ||||
Tibet Starlight Galaxy Investment Center |
Closing Date | 9/30/2020 | 2/2/2018 | 1/15/2013 | 12/1/2009 | |
---|---|---|---|---|---|
Fund | 四期人民币基金 (RMB Fund IV) | Legend Star Fund III | Suzhou Xinglian Tongdao Angel Investment Center LP | Legend Star Angel Fund | Tibet Starlight Galaxy Investment Center |
Fund Type | |||||
Status | |||||
Amount | $119.18M | ||||
Sources | 1 |
Legend Star Team
2 Team Members
Legend Star has 2 team members, including current Managing General Partner, Xudong Tang.
Name | Work History | Title | Status |
---|---|---|---|
Xudong Tang | Managing General Partner | Current | |
Name | Xudong Tang | |
---|---|---|
Work History | ||
Title | Managing General Partner | |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.